Colgate-Palmolive (NYSE:CL) Stock Sold Off Rep. Kevin Hern

Key Points

• Rep. Kevin Hern sold $1,001–$15,000 of Colgate-Palmolive shares on August 19 through the Hern Family Foundation account, alongside sales of several other stocks in August.
• Colgate-Palmolive shares recently traded around $90.21, while the company reported quarterly EPS of $0.99, beating estimates, and revenue rose 4.9% year over year to $5.36 billion.
• The company pays a quarterly dividend of $0.53 per share, equivalent to a 2.4% annual yield. Wall Street analysts maintain a “Moderate Buy” consensus with an average price target of $99.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Colgate-Palmolive Company NYSE: CL. In a filing disclosed on September 01st, the Representative disclosed that they had sold between $1,001 and $15,000 in Colgate-Palmolive stock on August 19th. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Marsh & McLennan Companies NYSE: MRSH on 8/24/2026.
• Sold $15,001 - $50,000 in shares of Medtronic NYSE: MDT on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Home Depot NYSE: HD on 8/24/2026.
• Sold $50,001 - $100,000 in shares of Procter & Gamble NYSE: PG on 8/24/2026.
• Sold $1,001 - $15,000 in shares of Lowe's Companies NYSE: LOW on 8/24/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Veralto NYSE: VLTO on 8/21/2026.
• Sold $15,001 - $50,000 in shares of Honeywell Aerospace NASDAQ: HONA on 8/19/2026.
• Sold $1,001 - $15,000 in shares of Biogen NASDAQ: BIIB on 8/18/2026.
• Sold $1,001 - $15,000 in shares of Anheuser-Busch InBev SA/NV NYSE: BUD on 8/18/2026.

Colgate-Palmolive Trading Up 0.6%

NYSE:CL opened at $90.21 on Thursday. The stock has a market cap of $71.91 billion, a PE ratio of 35.80, a price-to-earnings-growth ratio of 4.18 and a beta of 0.33. Colgate-Palmolive Company has a fifty-two week low of $74.54 and a fifty-two week high of $99.33. The company has a debt-to-equity ratio of 13.82, a current ratio of 1.03 and a quick ratio of 0.67. The stock's 50-day moving average is $91.97 and its two-hundred day moving average is $89.92.

Colgate-Palmolive (NYSE:CL - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $0.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.95 by $0.04. Colgate-Palmolive had a net margin of 9.68% and a return on equity of 464.63%. The business had revenue of $5.36 billion during the quarter, compared to analyst estimates of $5.36 billion. During the same period in the prior year, the firm earned $0.92 earnings per share. The firm's revenue was up 4.9% compared to the same quarter last year. As a group, equities research analysts forecast that Colgate-Palmolive Company will post 3.87 earnings per share for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Monday, July 20th were given a dividend of $0.53 per share. The ex-dividend date was Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.4%. Colgate-Palmolive's dividend payout ratio (DPR) is presently 84.13%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CL shares. Royal Bank Of Canada increased their target price on shares of Colgate-Palmolive from $102.00 to $104.00 and gave the stock an "outperform" rating in a research report on Monday, August 3rd. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Colgate-Palmolive in a research note on Friday, July 31st. Citigroup increased their price objective on Colgate-Palmolive from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. Sanford C. Bernstein reissued a "market perform" rating on shares of Colgate-Palmolive in a research report on Thursday, August 13th. Finally, Barclays boosted their target price on Colgate-Palmolive from $80.00 to $87.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 21st. Twelve equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $99.00.

Insider Buying and Selling

In related news, CEO Noel R. Wallace sold 161,021 shares of the business's stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $91.92, for a total value of $14,801,050.32. Following the completion of the sale, the chief executive officer directly owned 362,231 shares in the company, valued at approximately $33,296,273.52. The trade was a 30.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Panagiotis Tsourapas sold 10,000 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $92.05, for a total value of $920,500.00. Following the transaction, the chief operating officer owned 64,901 shares in the company, valued at approximately $5,974,137.05. This trade represents a 13.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 175,191 shares of company stock worth $16,110,903. 0.43% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CL. Range Advisory LLC acquired a new stake in shares of Colgate-Palmolive in the 2nd quarter valued at $276,000. Corient Private Wealth LP increased its position in Colgate-Palmolive by 29.0% during the second quarter. Corient Private Wealth LP now owns 639,604 shares of the company's stock worth $58,639,000 after buying an additional 143,812 shares during the last quarter. Amundi raised its holdings in Colgate-Palmolive by 19.9% during the second quarter. Amundi now owns 6,218,257 shares of the company's stock valued at $570,090,000 after buying an additional 1,033,918 shares in the last quarter. Groupe la Francaise lifted its position in shares of Colgate-Palmolive by 47.9% in the second quarter. Groupe la Francaise now owns 205,115 shares of the company's stock worth $18,750,000 after buying an additional 66,392 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Colgate-Palmolive during the 2nd quarter worth about $111,110,000. Institutional investors and hedge funds own 80.41% of the company's stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company's core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source